Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Roivant Sciences ( (ROIV) ) has provided an update.
On March 3, 2026, Roivant subsidiary Priovant Therapeutics said the U.S. Food and Drug Administration accepted its New Drug Application for brepocitinib to treat dermatomyositis and granted the filing Priority Review. The FDA set a Prescription Drug User Fee Act target action date in the third quarter of 2026, positioning brepocitinib for a potential U.S. launch at the end of September 2026 if approved.
The Priority Review is backed by positive Phase 3 VALOR trial data, the largest and longest interventional dermatomyositis study, in which brepocitinib 30 mg showed statistically significant and clinically meaningful benefits across primary and key secondary endpoints versus placebo. If approved, brepocitinib would become the first targeted therapy for dermatomyositis, potentially reshaping care for patients reliant on chronic high-dose steroids and enhancing Roivant’s presence in autoimmune therapeutics.
Priovant reported that serious infections were more frequent with brepocitinib 30 mg than placebo but were generally manageable, while malignancies, cardiovascular and thromboembolic events occurred more often in the placebo arm, supporting a safety profile comparable to existing JAK and TYK2 inhibitors. The breadth of the VALOR safety database and inclusion of patients with significant comorbidities may bolster regulatory confidence and strengthen the drug’s commercial case in a high unmet-need market.
The most recent analyst rating on (ROIV) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Roivant Sciences stock, see the ROIV Stock Forecast page.
Spark’s Take on ROIV Stock
According to Spark, TipRanks’ AI Analyst, ROIV is a Neutral.
The score is driven most by mixed financial performance (strong, low-debt balance sheet but ongoing losses and cash burn). Offsetting this, the earnings call was notably positive on clinical progress and upcoming catalysts with substantial cash runway, and technicals show an established uptrend, though near-term momentum looks stretched. Valuation is constrained by lack of profitability (negative P/E).
To see Spark’s full report on ROIV stock, click here.
More about Roivant Sciences
Priovant Therapeutics, a subsidiary of Roivant Sciences, is a biotechnology company focused on developing novel therapies for autoimmune diseases with high morbidity and limited treatment options. Its lead asset, brepocitinib, is an oral dual TYK2/JAK1 inhibitor targeting key cytokines involved in autoimmunity and is being advanced across multiple late-stage programs, including dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis.
Roivant Sciences, listed on Nasdaq as ROIV, leverages subsidiary companies like Priovant to develop and commercialize innovative therapies across specialized disease areas. Through this model, Roivant concentrates on high-need indications, aiming to build a diversified pipeline of targeted treatments that can strengthen its position in the competitive biotech and immunology markets.
Average Trading Volume: 7,054,781
Technical Sentiment Signal: Buy
Current Market Cap: $20.11B
Learn more about ROIV stock on TipRanks’ Stock Analysis page.